Autoantibodies to joint-related peptides as predictive markers in early rheumatoid arthritis
Authors' conclusion
Autoantibodies against joint-related proteins at RA diagnosis predict remission with high specificity and, in combination with clinical factors, may guide future treatment decisions.
Study context
- Population
- New-onset RA patients from the Swedish BARFOT and TIRA-2 cohortsBARFOT and TIRA-2 cohorts
- Participants
- 1,986 patients
- Outcome
- Disease outcomes: Boolean remission 1.0, swollen joint count and radiographic destruction
Methodological detailsmultivariate logistic regression, zero-inflated negative binomial models, bead-based multiplex flow immunoassay
- Multivariate logistic regression
- Zero-inflated negative binomial models
- Bead-based multiplex flow immunoassay
Performance
As reported in the abstract
Prediction of disease outcome by autoantibodies to joint-related peptides (JointIDs)
- Boolean remission at 12 months, male patients positive for non-modified COL2 peptide antibodies: sensitivity
- 42%
- Boolean remission at 12 months, male patients positive for non-modified COL2 peptide antibodies: specificity
- 75%
- Absent citrullinated cartilage oligomeric protein (COMP) peptide antibodies and Boolean remission at 6 months: sensitivity
- 13%
- Absent citrullinated COMP peptide antibodies and Boolean remission at 6 months: specificity
- 99%
- Non-modified COL2 peptide positivity: reduction in frequency of swollen joints at 6 months
- 41%
- Non-modified COL2 peptide positivity: reduction in frequency of swollen joints at 12 months
- 33%
- Anti-CCP predicting joint destruction: specificity
- 58%
- Citrullinated COL2 and glucose-6-phosphate dehydrogenase peptide positivity predicting joint destruction: specificity
- 86%
- Citrullinated COL2 and glucose-6-phosphate dehydrogenase peptide positivity predicting joint destruction: sensitivity
- 39%
Original publication
Autoantibodies to joint-related peptides as predictive markers in early rheumatoid arthritis. Rheumatology (Oxford). Published 30 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →